Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis

Abstract

With the introduction of Janus kinase inhibitors like tofacitinib, the treatment landscape for ulcerative colitis (UC) is changing quickly. Response heterogeneity is still a significant clinical challenge in spite of its quick onset and oral convenience. Extending tofacitinib induction beyond the standard eight weeks can produce significant benefits in a subset of patients without sacrificing safety, according to evidence from pivotal trials and real-world studies. We review recent real-world evidence, highlight lessons learnt from extended induction therapy, and present a practical framework to help guide tailored treatment decisions in this editorial. After 16 weeks of prolonged induction, more than half of patients with moderate-to-severe UC experienced remission, with durable persistence and favorable safety, according to a multicenter 52-week real-world study published in this issue of the World Journal of Gastroenterology. Crucially, outcomes and maintenance dosing were impacted by modifiable factors like smoking and biologic exposure. Mechanistic findings support a response-guided rather than fixed-duration induction paradigm by indicating that immune kinetics, mucosal healing rates, and previous biologic exposure may account for delayed responses. An effective, patient-centered strategy that could maximize tofacitinib’s therapeutic potential and assist in guiding refractory UC patients towards long-term remission is extended induction.

Key Words: Tofacitinib; Ulcerative colitis; Induction therapy; Maintenance therapy; Janus kinase

Core Tip: Partial or delayed responders with ulcerative colitis can be saved by extending tofacitinib induction from 8 weeks to 16 weeks without raising safety concerns. Evidence from the real world shows that this approach, especially in patients with biologic experience, results in higher remission rates and long-lasting drug persistence. Instead of a strict 8-week limit, a structured, response-guided algorithm enables clinicians to address modifiable risk factors like smoking, maximize long-term outcomes, and customize therapy. Now, extended induction ought to be seen as a logical, scientifically supported part of customized tofacitinib treatment.

INTRODUCTION

With the growing use of Janus kinase (JAK) inhibitors, especially tofacitinib, the treatment of moderate-to-severe ulcerative colitis (UC) continues to change. Variability in treatment response is still a significant clinical challenge, despite its quick onset of action and oral administration. Extending the induction period beyond eight weeks may improve outcomes in certain patients without sacrificing safety, according to data from pivotal trials and real-world studies. This editorial examines practical methods to tailor and enhance tofacitinib therapy, practical implications, and the lessons learnt from extended induction.

In this issue of the World Journal of Gastroenterology, Tzouvala et al[1] present a timely multicentre study that addresses these precise questions. Their 52-week real-world data demonstrate that over half of patients with moderate-to-severe UC who received an extended 16-week induction with tofacitinib achieved clinical remission, with an impressive drug persistence rate of 75.7%. Crucially, the study provides valuable information for doctors: Over half of the attempts to de-escalate to 5 mg twice daily were successful, and patients with a history of biologic failure were more likely to require continuous 10 mg dosing for maintenance. Additionally, the finding that treatment discontinuation was significantly predicted by active smoking revealed a modifiable risk factor. By validating the extended induction strategy in a refractory, biologically experienced cohort, this study effectively contributes to trial data. It advances the field towards a more customized approach to tofacitinib treatment in UC, indicating that we can optimize long-term outcomes for those who require it most with careful patient selection and dose adjustment.

The intracellular enzymes known as JAKs, which are involved in cytokine signaling pathways, are blocked by tofacitinib. This mechanism regulates the inflammatory response in inflammatory bowel disease. Extraintestinal manifestations, such as spondylarthritis and arthralgias, are common in up to 20% of UC patients and are successfully treated by this mechanism. Depending on the severity of both UC and axial or peripheral spondylarthritis, tofacitinib may be a good alternative to anti-tumor necrosis factor (TNF) drugs in these patients[2,3].

With a burgeoning arsenal of options that includes immunomodulators, biologics, and small molecules, the therapeutic landscape for inflammatory bowel disease is constantly changing. Treatment objectives have evolved from symptomatic relief to mucosal healing and deep remission, aiming for true disease modification. Even though tofacitinib is a major advancement, research continues new strategies such as optimizing mesalazine delivery[4], employing engineered micro/nanomaterials to modulate the gut microbiota[5], and exploring preventive approaches in high-risk populations[6].

THE ORIGINAL INDUCTION TRIALS: LESSONS LEARNED

Tofacitinib demonstrated strong efficacy in the pivotal OCTAVE induction 1 and 2 trials; 10 mg twice daily for eight weeks produced a significant clinical and endoscopic remission when compared to placebo. Approximately one-third of patients had not seen a clinical response by week eight. Even though patients who demonstrated a response after eight weeks continued maintenance therapy, many initial non-responders were excluded from the OCTAVE sustain trial. This brings up an important question: Would further induction be beneficial for these “delayed responders”[7]?

Important information was obtained from a post hoc analysis of the long-term extension study OCTAVE open. About one-third of patients who did not respond at week eight but continued to take 10 mg twice daily for an additional eight weeks experienced a clinical response or remission by week sixteen[8]. This research presented the idea of extended induction for partial or late responders and questioned the conventional fixed 8-week induction window.

EVIDENCE FROM THE REAL WORLD ENDORSING EXTENDED INDUCTION

The extension of tofacitinib induction to 16 weeks has been shown to increase response and remission rates in a number of cohorts[9-12]. This is especially true for patients with a high inflammatory burden or previous biologic exposure.

For instance, prolonged induction produced clinically significant increases in Mayo score without a rise in adverse events, according to Sandborn et al[10]. A 16-week extended induction strategy also produced additional remission in 20%-35% of patients who were initially categorized as non-responders, according to retrospective cohorts from Europe and Japan[10-12]. Crucially, prolonged induction did not result in an increase in safety outcomes like thromboembolic events or herpes zoster, highlighting the viability of customized therapy duration (Table 1)[7,8,10-16].

Table 1 Studies of extended induction tofacitinib therapy in ulcerative colitis.

Ref.	Design	Patients	Clinical response	Adverse events	Severity
Sandborn et al[8]	Phase 2/3 randomized controlled	Moderate to severe colitis	52% delayed responders. 44% remission at 36th month		Similar 8 weeks vs 16 weeks
Sandborn et al[7]	Three phase 3 randomized controlled trials (OCTAVE induction 1/2, sustain)	Moderate to severe ulcerative colitis, prior conventional or biologic therapy	18.5% (induction 1), 16.6% (induction 2), 18.5% (induction 1), 16.6% (induction 2)	Infections, herpes zoster, non-melanoma skin cancer, cardiovascular events, lipid changes	Serious infections higher in induction; similar in maintenance
Sandborn et al[10]	Phase 2 randomized controlled trial, dose-ranging	Moderate to severe ulcerative colitis. 194 patients	61% (10 mg twice daily), 78% (15 mg twice daily). Remission: 48% (10 mg twice daily), 41% (15 mg twice daily	Lipid changes, neutropenia
Paschos et al[11]	Systemic review and meta-analysis	Moderate to severe ulcerative colitis, 29%-46.7% prior anti-tumor necrosis factor therapy, mean age 40-43 (1220 patients)	Odds ratio = 2.95 (response). Remission: Odds ratio = 3.84 (response)	Infections (nasopharyngitis), adverse events	Serious infections are rare similar to placebo
Lin et al[12]	Systemic review and meta-analysis	Moderate to severe ulcerative colitis, partial Mayo score 5-9, extensive disease, 26-46 years, 39%-69% male (2612 patients)	58% (8 weeks), 61% (12-16 weeks), 51% (24-26 weeks), 51% (52 weeks). Remission: 39% (8 weeks), 43% (12-16 weeks), 40% (24-26 weeks), 43% (52 weeks)	Serious infections 1.6-1.7 per 100 patient-years, herpes zoster 3.2-3.3 per 100 patient-years, cardiovascular events 0.16-0.29 per 100 patient-years
Taxonera et al[13]	Systematic review and meta-analysis of real-world studies	Moderate to severe, highly refractory ulcerative colitis, 11.6% biologic-naive (1162 patients)	62.1% (8 weeks), 64.2% (12-16 weeks), 50.8% (24 weeks), 41.8% (52 weeks). Remission: 34.7% (8 weeks), 47% (12-16 weeks), 38.3% (24 weeks)	8.9 per 100 patient-years (serious adverse events), 6.9 per 100 patient-years (herpes zoster)	Similar
Taneja et al[14]	Systematic review and meta-analysis (randomized controlled trials and real-world studies)	Moderate to severe ulcerative colitis, biologic-naive and experienced	59.4% (8 weeks), 49% (6 months), 51% (1 year). Remission: 29.8% (8 weeks), 32.3% (6 months), 38% (1 year)	4.4 per 100 patient-years (infections), 0.9 per 100 patient-years (cardiovascular/malignancy)	Higher at higher dose
Lichtenstein et al[15]	Phase 3, multicenter, open-label extension	Moderate to severe ulcerative colitis, prior randomized controlled trial participants (914 patients)		Serious adverse events 10.4%, severe 78%, serious infections 2.6% (5 mg), 1.8% (10 mg), malignancy 1.2% (10 mg)
Chaparro et al[16]	Prospective, multicenter, real-world registry (ENEIDA)	Refractory ulcerative colitis, prior biologic failure, partial Mayo score (113 patients)	60% (8 weeks). Remission: 31% (8 weeks)	Adverse events (hypercholesterolemia, herpes zoster, infections), discontinuations	15% adverse events, 6% discontinued for adverse events

MECHANISTIC JUSTIFICATION: WHY IS EXTENDED INDUCTION REQUIRED FOR CERTAIN PATIENTS?

Treatment response heterogeneity to tofacitinib is probably caused by differences in immune dynamics, mucosal healing kinetics, and pharmacogenetic factors. The JAK-signal transducer and activator of transcription pathway, which is essential to UC pathophysiology, mediates cytokine signaling for interleukin (IL)-2, IL-6, IL-7, and interferons[17]. Patients with deep ulcerations, elevated C-reactive protein (CRP), or severe baseline inflammation may require a longer duration of pathway inhibition to achieve mucosal repair. Furthermore, the advantages of JAK inhibition may be delayed by previous exposure to biologics, especially anti-TNF agents, which may alter immune responsiveness or downregulate receptor pathways[18]. An adaptive induction strategy, which is guided by response evaluation at week eight rather than an abrupt change in treatment, is supported by these clinical and biological considerations.

Clinical decision-making framework

Three key steps comprise a practical strategy for maximizing tofacitinib induction in UC: First induction (weeks 0-8): Start with 10 mg twice a day; At week four, assess symptoms, CRP, and partial Mayo score. Evaluation of response at week 8: Responders: Go to maintenance (the lowest effective dose or 5 mg twice daily). Partial/non-responders: For an additional eight weeks, take 10 mg twice a day (extended induction). Week 16 reassessment: If there is no discernible improvement, stop maintaining late responders. Lipid profile, infection risk assessment, and zoster vaccination status are among the parameters that are monitored during induction. Extended induction can be used safely and effectively with the help of such structured assessment.

Clinical impact: Better remission maintenance without increasing safety concerns

Patients who achieve remission following prolonged induction have similar long-term outcomes to early responders during maintenance, according to several real-world registries[9,19]. Furthermore, the extended group does not have a noticeably higher rate of discontinuation owing to side effects or ineffectiveness. Safety concerns regarding tofacitinib particularly venous thromboembolism and major adverse cardiovascular events have prompted careful dose management. However, observational data show that with proper patient selection and vigilance, temporary extended induction (up to 16 weeks) does not significantly increase these risks[20].

Integration with treatment sequencing and real-world practice

Tofacitinib is still one of the most important advanced UC treatments available, particularly for patients who have had numerous biologic failures or who are intolerant to vedolizumab and anti-TNF. Because it offers a therapeutic bridge, more patients can benefit from prolonged induction before switching to alternative mechanisms. Even though new selective JAK1 inhibitors like upadacitinib and filgotinib are very effective, worries about long-term safety, cost, and accessibility still exist[21]. This makes evidence-based extended induction, which optimizes tofacitinib’s therapeutic window, a reasonable and cost-effective strategy for attaining long-lasting mucosal healing.

CONCLUSION

The increasing popularity of extended induction calls for its incorporation into treatment algorithms and prospective validation in randomized controlled trials. The role of therapeutic drug monitoring in small-molecule therapies, the best time to taper doses, and biomarkers predictive of delayed response remain active areas of investigation. Furthermore, machine learning-based predictive models that incorporate endoscopic, serologic, and clinical data may assist doctors in determining who should undergo extended induction up front. Such customized methods could replace the rigid 8-week induction paradigm with a framework that is adaptable and patient-specific.